Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The only thing I will speculate is the results must carry at least a positive outlook, otherwise the investors call would be before the market opens on Monday morning.
One would think if the results could be misinterpreted (as so so or negative)they would want to have a call to explain results to those that did not hear the presentation on Saturday.
I’m very excited to see the results. If they are positive in PC which is a grim prognosis that historically is very tough to treat, it will bode well for the platform in other cancers. Which could further enhance the true value of the approach and technology.
18 days until....
I’m not going to speculate but my understanding is the investor’s call is Monday after the market closes.
Someone can correct me if I am wrong...
Ye there are not many on the board and I do agree it’s a really great opportunity. I got in at $17.16 but not with all the shares I would like to have.... but at least I’m in!
Anyone know the fully diluted share count including the warrants?
With regards to PC is Celgene’s Abraxane the most common first line method for treatment? Was curious if anyone knows the typical therapeutic route that is the SOC(Standard of Care) for treatment?
I was reading information regarding the prognosis of the disease and even with the use of Abraxane. This speaks to the aggressive nature of this type of cancer, which would allow for much improvement.
Here is a link to the info....
https://www.abraxanepro.com/metastatic-pancreatic-cancer/
Nice! Wish I would I could say I got in around that time. Congrats to you!
There is still way more upside. I’ll be adding on any pullbacks...
Thanks Phantom and Inovio for your insights on timelines. I have to believe the PC data will be positive. Nonetheless, I added more shares today with the intention of increasing my position in the next several trading sessions.
If the PC data is seen as less than positive by the market I will use it as an opportunity to get more shares in anticipation of events later in the year.
Not too speculate as I know this has been discussed. I do find it interesting that the $200 million shelf was filed on Friday. The only near term catalyst is the PC data, otherwise dilution could potentially occur at the current share price. If no capital raise prior to the presentation should that be taken as a good sign?
Also, What other big catalyst are there through the end of the year? Considering the current cash situation and burn rate funds will have to be raised before EOY, correct?
From the looks of things we may be the only two here ??
Looking to add more if this thing when this move slows down...which may not happen until mid $20’s
Nice move this morning...glad to be in around $17 a couple of weeks ago. Anybody else active on the board?
Found this information granted it’s from a different event...
https://www.aacr.org/Documents/1707050_18AM_Call_NC_rev4.pdf
Begins on Page 27...
“Presentation of Proffered Papers at the AACR Annual Meeting. Every proffered abstract
that has been accepted for publication in
the Proceedings must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session
to present the paper, he or she must contact the AACR Program Development Department
Phantom...
If the presentation is listed on the AACR website does that mean it is confirmed?
https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=178&DetailItemID=1011
Looks like they are presenting July 20th in the morning sessions.
Title is: Targeting pancreatic cancer using non-engineered, multiantigen-specified T cells (TACTOPS)
Presenter: Brandon G. Smaglo
Baylor College of Medicine
Houston, TX
Thank you for the insight!
Thanks Micro! I PM’d Marker Therapeutics via FB and was told it would be released some time in Q3 with no definitive date. Hopefully it is in July...
Is this a full data readout or just an interim look? Does anyone have a link to the trial in clinical trials?
Thank you for that information!
Does anyone have specifics on when the pancreatic data will be released? I tried finding the trial in clinical trials.gov but did not have any luck.
TIA
Read the total heading “ Distinct Roles of EPA and DHA in Cellular Function and Atherosclerosis”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330561/
Great news! I did not know it had been moved back. Very nice!
Thanks for posting!
Where did you see the STRENGTH trial is postponed?
Roger! Thanks for clarifying
Where do you see it will be published by June 6th? From what I read it will be September...
CardMD I have been following your posts. Would you pm me your email address. I would like to shoot you an email if possible and you do not mind. Thanks!
What area of the country are you located?
Do you have a link to the article?
Interim analysis is in the fall. If no unblinding occurs then data will not come until 2017...I would suspect middle of 2017
Got it! Thanks for the help!
Dane or anyone else....I'm catching up for the day. Can someone tell me about the response from IR regarding the trials and the 2 yr extension?
Thanks for the clarification on that. Been a crazy morning and caught the statement but couldn't read between the lines to see the positive concerning this finding. Very positive indeed!
Amen! Been holding and checking in occasionally. The motto of only risking what you can afford to loose makes the ups and downs easier. And even easier when you don't watch it day to day!!!
GLTY
EBIO....glad you were not in prior to data release. I'd play it as a bounce still. AIMO
Here's my post on EBIO several months ago...
Re: ash111 Post# 11226
EBIO....I think the risk here is very high. After looking at their phase 2 data for ocular allergic conjunctivitis I discovered that the primary endpoint for ocular itching was not met. They had good feedback on the secondary endpoint and those were statistically significant. All this info can be found in the following link. The second link is the PII trial and design info.
http://ir.elevenbio.com/releasedetail.cfm?releaseid=874221
https://clinicaltrials.gov/ct2/show/NCT02082899?term=Eleven+biotherapeutics&rank=3
So the phase III design:
primary endpoint is "morning" ocular itching.
Secondary endpoint a are:
"late afternoon" ocular itching
"Evening" ocular itching
Here is link to study design:
https://clinicaltrials.gov/ct2/show/NCT02492321?term=Eleven+biotherapeutics&rank=1
I'm not saying they will not meet there endpoint as I'm sure this design was based of the findings in their PII.
I have not been able to identify how or if the scoring of ocular itching is different in their PIII vs PII. This could be valuable info for making a better informed decision of holding through data or not.
The date for data release is set for sometime in Q1 of 2016 and not Nov-December. This is from the CEO on August 12th press release. Found here...
http://www.businesswire.com/news/home/20150812005116/en/Eleven-Biotherapeutics-Announces-Patients-Dosed-EBI-005-Phase#.Vc4yX4r3bCQ
I MAY enter on a large pullback and play it as a catalyst play and IF I enter I will not hold through data.
These are just my opinions please do your own DD.
GL
Replies:
thanks it's a good DD.
ash111 on 8/14/2015 4:07:40 PM
Report TOS
I think you are spot on maskone!
Wolf I sent you a PM. Check it out as quickly as you can!
Thanks JohnnyB!
Cbd...the only problem with off label is insurance companies do not always approve for this type of use. The patient can still get the medication but at an increased price. This can be costly and an obstacle for patients looking to use it for an off label disease.
CTRV...joined this one. On the pullback this morning. May look to add more before next week. Starter position currently...
Nothing malicious about that wolf. I have the same ideas about raising money as well. End game I'm not concerned but I like you want more shares too.
I agree the board has hanged quite dramatically in the last 2 weeks. A lot of new faces that I haven't seen post on here since I started following in July. Let's see who sticks out the rollercoaster ride till the end. Hope you stick it out my friend!
GL
IMUC....data update at 6:03 am....
http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#imuc
LLTP...nice alert. This one is zooming today!